-
4 updates on Mounjaro, Ozempic
In a phase 3 trial spanning three years, weekly injections of tirzepatide reduced the risk of Type 2 diabetes by 94%, Eli Lilly said Aug. 20. -
Organization creates 15th specialty pharmacy certification
The Board of Pharmacy Specialties is developing an exam for a new specialty pharmacy certification. -
Premier honors 6 health system pharmacies
Premier recently recognized six U.S. hospitals and health system pharmacies and one pharmacist through the company's 2024 Premier Pharmacy awards. -
FDA approves first-line treatment for lung cancer
Johnson & Johnson's oncology treatment regimen, Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib), is now approved as a first-line therapy, the drugmaker said Aug. 20. -
A potential AI tool for hospital pharmacies
A context-aware ChatGPT might be of use in pharmacies, according to a recent study. -
Maine hospital partners with local pharmacy for outpatient services
Northern Maine Medical Center in Fort Kent is moving its outpatient pharmacy services to St. John Valley Pharmacy, an independently owned pharmacy in the area. -
Antibiotics versus surgery for appendicitis: What to know
An alternative option to appendectomies is becoming more mainstream, The Washington Post reported Aug. 17. -
The gabapentin popularity boom
Gabapentin is FDA-approved for epileptic seizures and postherpetic neuralgia, which is lasting pain after a shingles infection. Its off-label uses are climbing as physicians discover new applications, The New York Times reported Aug. 17. -
Drugmaker to ramp up production of mpox vaccine
Denmark-based Bavarian Nordic said Aug. 17 it plans to ramp up mpox vaccine manufacturing. -
Some physicians get comfortable with compounded weight loss drugs
Anecdotally, some physicians are getting more comfortable prescribing compounded versions of popular weight loss drugs Wegovy and Zepound, which are both in short supply, NBC News reported Aug. 16. -
Lykos to lay off 75% of workforce in wake of PTSD drug rejection
Lykos Therapeutics, the manufacturer of midomafetamine (MDMA), which had been tested for PTSD treatment, will reduce its workforce by 75% after the FDA rejected the company's new drug application. -
High costs prompt patients to tamper with Ozempic, Mounjaro
Some patients are dose splitting their GLP-1 injection pens as they struggle to pay thousands of dollars for the diabetes and weight loss medications, The Atlantic reported Aug. 15. -
5 drugs now in shortage
About two-thirds of providers recently told Premier their teams are spending more than 10 hours per week mitigating supply chain challenges and shortages. -
Eli Lilly takes action over Zepbound, Mounjaro copycats
Drug manufacturer Eli Lilly & Co. has sent cease-and-desist letters to U.S. healthcare providers demanding an end to the promotion and sale of copycat versions of the company's Mounjaro and Zepbound GLP-1 drugs, Bloomberg reported Aug. 15. -
CMS' negotiated drug prices: 12 notes
For the first time, the largest buyer of pharmaceuticals in the U.S. — Medicare, which covered more than 67 million people as of April — has bargaining power in an industry worth $640 billion. -
Mark Cuban to publish Cost Plus Drug contracts
"Transparency," a growing buzzword in the pharmaceutical industry, is making another premiere at Mark Cuban Cost Plus Drug Co. -
First Walgreens pharmacists look to unionize
The first group of Walgreens employees are seeking to join a new national union of retail pharmacy professionals, MedPage Today reported Aug. 12. -
CMS' 10 negotiated drug prices
After months of failed litigation from drugmakers, CMS released negotiated list prices for 10 of the country's most expensive drugs. -
Heat spells trouble for mail-order medications
Mail-order pharmacies run well-coordinated supply chain operations to ensure medications are safely delivered to patients' doorsteps, but extreme temperatures are complicating the process, The New York Times reported Aug. 13. -
UVA Health doubles specialty pharmacy
Charlottesville, Va.-based UVA Health's specialty pharmacy has expanded its footprint at the university-owned North Fork industrial park.
Page 6 of 50